New Lenvima/Keytruda combo data in a range of cancers presented at ESMO 2020

pharmafile | September 21, 2020 | News story | Research and Development, Sales and Marketing Cancer, ESMO2020, Eisai, Lenvima, MSD, keytruda 

New data from two studies investigating the combination of Eisai’s multiple receptor tyrosine kinase inhibitor Lenvima (lenvatinib) and MSD’s blockbuster anti-PD-1 therapy Keytruda (pembrolizumab) were revealed at the European Society for Medical Oncology (ESMO) Virtual Congress 2020.

In the first study, the combo was found to generate an objective response rate (ORR) of 21.4% in the treatment of unresectable or advanced melanoma which has progressed following anti-PD-1/PD-L1 therapy, representing 22 out of 103 patients.

This rate was found to be higher in those who had seen disease progression after receiving treatment with an anti-PD-1/L1 in addition to anti-CTLA-4 therapy, recorded at 31%, or nine of the 29 participants in this population.

Furthermore, median overall survival for the combo was demonstrated to be 13.9 months, with a nine-month overall survival rate of 65.4%.

In a separate Phase 2 study examining the efficacy of the combo in the treatment of ovarian, gastric, colorectal and biliary tract cancer, triple-negative breast cancer and glioblastoma multiforme, ORR was found to vary between 9.7% and 32.3%.

Miguel Marcão, Vice President of Eisai’s EMEA Oncology Business Group, said the data “represents important progress, particularly in advanced cancer types where treatment options can be severely limited for patients, leading to a high unmet need,” adding, “We remain committed to delivering on our strategic collaboration with Merck and exploring the potential of lenvatinib across multiple tumour types, to ensure we can help as many patients as possible.”

Matt Fellows

Related Content


AstraZeneca shares oncology data at ASCO 2023

AstraZeneca plans to share data from its oncology pipeline at the American Society of Clinical …

AstraZeneca announces positive results from phase 3 trial for Tagrisso plus chemotherapy

AstraZeneca has announced positive results from the FLAURA2 phase 3 trial which showed that Tagrisso …

Thermo Fisher and Pfizer collaborate on NGS-based cancer tests

Scientific equipment provider Thermo Fisher and US pharmaceutical firm Pfizer have announced a collaboration to …

Latest content